

Biotec has entered into a supply agreement for M-Glucan to the pet sector

(Tromsø, 25 September 2017) Biotec Pharmacon ASA's ("Biotec", OSE: BIOTEC) subsidiary Biotec BetaGlucans has today signed a supply agreement for M-Glucan™ to a customer within the pet food segment

Deliveries under the agreement will commence in the fourth quarter of 2017 and run through 2020. Expected revenues for the contract period is around NOK 3 million depending on customer sales of pet food containing M-Glucan as an ingredient.

This supply agreement represents the first supply agreement outside of the marine farmed food segment and is part of Biotec BetaGlucans strategy to expand supply of M-Glucan into other business segments.

"We're really pleased to sign this agreement as it represents a new market segment and opportunities for M-Glucan. Even though the contract is relative small in volume, it will be important as a reference for further agreements in this segment, says Biotec Pharmacon's CFO Børge Sørvoll.

For more information, please contact:

Børge Sørvoll,
CFO

tel +47 952 90 187

borge.sorvoll@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.